Twist Bioscience (TWST) and Ginkgo Bioworks (DNA) announced they entered into an updated collaboration renegotiated from a prior 2022 contract. Under the revised three-year, $15M agreement, Ginkgo will continue ordering Twist’s DNA products with preferential pricing but no purchase minimums, prepaying annually. Twist receives licenses and assignments for certain long DNA and other technology and reagents as credit against the 2022 deal, while Ginkgo retains rights to practice the transferred IP.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cathie Wood’s ARK Investment buys 283.2K shares of Twist Bioscience today
- Twist Bioscience price target lowered to $44 from $54 at Baird
- Cautious Outlook on Twist Bioscience Amidst Macroeconomic Challenges and Premium Valuation
- Twist Bioscience price target lowered to $33 from $40 at JPMorgan
- Twist Bioscience Reports Record Revenue and Strategic Spin-Out